396 related articles for article (PubMed ID: 17152090)
21. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Clark MJ; Traynor JR
J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
[TBL] [Abstract][Full Text] [Related]
22. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
Pak Y; Kouvelas A; Scheideler MA; Rasmussen J; O'Dowd BF; George SR
Mol Pharmacol; 1996 Nov; 50(5):1214-22. PubMed ID: 8913353
[TBL] [Abstract][Full Text] [Related]
23. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
24. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
25. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
[TBL] [Abstract][Full Text] [Related]
26. Opioid-induced regulation of gene expression in PC12 cells stably transfected with mu-opioid receptor.
Zarnegar P; Persson AI; Ming Y; Terenius L
Neurosci Lett; 2006 Apr; 396(3):197-201. PubMed ID: 16377088
[TBL] [Abstract][Full Text] [Related]
27. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
28. Up-regulation of spinal mu-opioid receptor function to activate G-protein by chronic naloxone treatment.
Narita M; Mizoguchi H; Nagase H; Suzuki T; Tseng LF
Brain Res; 2001 Sep; 913(2):170-3. PubMed ID: 11549382
[TBL] [Abstract][Full Text] [Related]
29. Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse.
Mizoguchi H; Wu HE; Narita M; Hall FS; Sora I; Uhl GR; Nagase H; Tseng LF
Neuroscience; 2002; 115(3):715-21. PubMed ID: 12435410
[TBL] [Abstract][Full Text] [Related]
30. Involvement of spinal protein kinase Cgamma in the attenuation of opioid mu-receptor-mediated G-protein activation after chronic intrathecal administration of [D-Ala2,N-MePhe4,Gly-Ol(5)]enkephalin.
Narita M; Mizoguchi H; Narita M; Nagase H; Suzuki T; Tseng LF
J Neurosci; 2001 Jun; 21(11):3715-20. PubMed ID: 11356858
[TBL] [Abstract][Full Text] [Related]
31. mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy.
Selley DE; Sim LJ; Xiao R; Liu Q; Childers SR
Mol Pharmacol; 1997 Jan; 51(1):87-96. PubMed ID: 9016350
[TBL] [Abstract][Full Text] [Related]
32. Effects of intracerebroventricular administration of beta-funaltrexamine on DAMGO-stimulated [35S]GTP-gamma-S binding in rat brain sections.
Martin TJ; Sim LJ; Selley DE; deMontis MG; Childers SR
Synapse; 1997 Nov; 27(3):177-82. PubMed ID: 9329153
[TBL] [Abstract][Full Text] [Related]
33. Anti-mu opioid antiserum against the third external loop of the cloned mu-opioid receptor acts as a mu receptor neutral antagonist.
Guarna M; Bartolini A; Ghelardini C; Galeotti N; Bracci L; Stefano GB; Bianchi E
Brain Res Mol Brain Res; 2003 Nov; 119(1):100-10. PubMed ID: 14597234
[TBL] [Abstract][Full Text] [Related]
34. A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.
Brasel CM; Sawyer GW; Stevens CW
Eur J Pharmacol; 2008 Dec; 599(1-3):36-43. PubMed ID: 18930720
[TBL] [Abstract][Full Text] [Related]
35. Effect of agmatine on DAMGO-induced mu-opioid receptor down-regulation and internalization via activation of IRAS, a candidate for imidazoline I(1) receptor.
Gao Y; Li F; Wu N; Su RB; Liu Y; Lu XQ; Liu Y; Li J
Eur J Pharmacol; 2008 Dec; 599(1-3):18-23. PubMed ID: 18845140
[TBL] [Abstract][Full Text] [Related]
36. G protein activation by endomorphins in the mouse periaqueductal gray matter.
Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
[TBL] [Abstract][Full Text] [Related]
37. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain.
Chaipatikul V; Loh HH; Law PY
J Pharmacol Exp Ther; 2003 Jun; 305(3):909-18. PubMed ID: 12626655
[TBL] [Abstract][Full Text] [Related]
38. Receptor endocytosis counteracts the development of opioid tolerance.
Koch T; Widera A; Bartzsch K; Schulz S; Brandenburg LO; Wundrack N; Beyer A; Grecksch G; Höllt V
Mol Pharmacol; 2005 Jan; 67(1):280-7. PubMed ID: 15475572
[TBL] [Abstract][Full Text] [Related]
39. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
40. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
